Cipla Ltd.

Cipla is reportedly planning to re-start supplying anti-HIV drugs to the National Aids Control Organisation (Naco) in the next two months.

The Mumbai-based drug company had, during the second half of last year, stopped bidding for Naco tenders. The company had participated in the Naco’s paediatric tenders, which were being evaluated.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.